Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VNDA
VNDA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VNDA News
EMA's CHMP Reaffirms Decision to Deny Change in Marketing Authorization for Hetlioz (Tasimelteon)
3d ago
moomoo
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development
Mar 19 2026
PRnewswire
Vanda Pharmaceuticals Raises Concerns Over FDA's New Draft Guidance
Mar 19 2026
Newsfilter
Wall Street Analysts Adjust Ratings
Mar 05 2026
Benzinga
FDA Grants Hearing for Vanda's Hetlioz Jet Lag Drug
Mar 03 2026
seekingalpha
FDA Grants Vanda Hearing on Jet Lag Drug Rejection
Mar 03 2026
stocktwits
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
Mar 03 2026
PRnewswire
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
Mar 03 2026
Newsfilter
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference
Feb 26 2026
PRnewswire
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference
Feb 26 2026
Newsfilter
Vanda Pharmaceuticals' New Drug Approved by FDA
Feb 25 2026
Benzinga
Vanda Pharmaceuticals Seeks FDA Approval for Imsidolimab
Feb 25 2026
stocktwits
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP
Feb 25 2026
PRnewswire
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP
Feb 25 2026
Newsfilter
FDA Approval of Bysanti Enhances Vanda's Portfolio
Feb 24 2026
Benzinga
Vanda Pharmaceuticals' Bysanti Receives FDA Approval
Feb 23 2026
Benzinga
Show More News
